Skip to main content
SpringerLink
Log in

Skin Manifestations in Rheumatologic Disorders

  • Chapter
Book cover Therapy of Skin Diseases

  • 1463 Accesses

Key Features

  • Cytokines including IL-18 play an important role in the pathogenesis.

  • High spiking fever and “rheumatoid rash” are characteristic, although skin manifestations vary.

  • NSAID monotherapy is effective only in minority.

  • Corticosteroids and DMARDs/immunosuppres-sants are used in cases resistant to NSAIDs.

  • TNF-α inhibitors are potential therapeutic agents effective for the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kadar J, Petrovicz E (2004) Adult-onset Still's disease. Best Pract Res Clin Rheumatol 18:663–676

    Article  PubMed  Google Scholar 

  2. Efthimiou P, Georgy S (2006) Pathogenesis and management of adult-onset Still's disease. Semin Arthritis Rheum 36:144–152

    Article  PubMed  CAS  Google Scholar 

  3. Hoshino T, Ohta A, Yang D et al (1998) Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 25:396–398

    PubMed  CAS  Google Scholar 

  4. Chen DY, Lan JL, Lin FJ et al (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63:1300–1306

    Article  PubMed  CAS  Google Scholar 

  5. Matsui K, Tsuchida T, Hiroishi K et al (1999) High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still's disease. Rheumatology (Oxford) 38: 477–478

    Article  CAS  Google Scholar 

  6. Kawashima M, Yamamura M, Taniai M et al (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 44:550–560

    Article  PubMed  CAS  Google Scholar 

  7. Sugiura T, Kawaguchi Y, Harigai M et al (2002) Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 3:394–399

    Article  PubMed  CAS  Google Scholar 

  8. Chen DY, Lan JL, Lin FJ et al (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 31:2189–2198

    PubMed  CAS  Google Scholar 

  9. Wouters JM, van de Putte LB (1986) Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med 61:1055–1065

    PubMed  CAS  Google Scholar 

  10. Masson C, Le Loet X, Liote F et al (1996) Comparative study of 6 types of criteria in adult Still's disease. J Rheumatol 23:495–497

    PubMed  CAS  Google Scholar 

  11. Reginato AJ, Schumacher HR Jr, Baker DG et al (1987) Adult onset Still's disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum 17:39–57

    Article  PubMed  CAS  Google Scholar 

  12. Pouchot J, Sampalis JS, Beaudet F et al (1991) Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70:118–136

    CAS  Google Scholar 

  13. Khraishi M, Fam AG (1991) Treatment of fulminant adult Still's disease with intravenous pulse methylprednisolone therapy. J Rheumatol 18:1088–1090

    PubMed  CAS  Google Scholar 

  14. Masson C, Le Loet X, Liote F et al (1995) Adult Still's disease. Part II. Management, outcome, and prognostic factors. Rev Rhum Engl Ed 62:758–765

    PubMed  CAS  Google Scholar 

  15. Fautrel B, Borget C, Rozenberg S et al (1999) Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26:373–378

    PubMed  CAS  Google Scholar 

  16. Mahmud T, Hughes GR (1999) Intravenous immunoglobu-lin in the treatment of refractory adult Still's disease. J Rheumatol 26:2067–2068

    PubMed  CAS  Google Scholar 

  17. Vignes S, Wechsler B, Amoura Z et al (1998) Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 16: 295–298

    PubMed  CAS  Google Scholar 

  18. Cefle A (2005) Leflunomide and azathioprine combination in refractory adult-onset Still's disease. Ann Pharmacother 39:764–767

    Article  PubMed  Google Scholar 

  19. Bennett AN, Peterson P, Sangle S et al (2004) Adult onset Still's disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil. Rheumatology (Oxford) 43: 795–799

    Article  CAS  Google Scholar 

  20. Cavagna L, Caporali R, Epis O et al (2001) Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 19:329–332

    PubMed  CAS  Google Scholar 

  21. Husni ME, Maier AL, Mease PJ et al (2002) Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 46:1171–1176

    Article  PubMed  CAS  Google Scholar 

  22. Benucci M, Li GF, Del Rosso A et al (2005) Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report. Clin Exp Rheumatol 23:733

    PubMed  CAS  Google Scholar 

  23. Asherson RA, Pascoe L (2002) Adult onset Still's disease: response to Enbrel. Ann Rheum Dis 61:859–860; author reply 60

    Article  PubMed  CAS  Google Scholar 

  24. Huffstutter JE, Sienknecht CW (2004) Treatment of resistant adult still disease with infliximab: a report of 2 cases. J Clin Rheumatol 10:218–221

    Article  PubMed  Google Scholar 

  25. Fautrel B, Sibilia J, Mariette X et al (2005) Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64:262–266

    Article  PubMed  CAS  Google Scholar 

  26. Yokota S, Miyamae T, Imagawa T et al (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52:818–825

    Article  PubMed  CAS  Google Scholar 

  27. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J (2005) Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 64:647–648

    Article  PubMed  CAS  Google Scholar 

  28. Fitzgerald AA, Leclercq SA, Yan A et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52:1794–1803

    Article  PubMed  CAS  Google Scholar 

  29. Stambe C, Wicks IP (1998) TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet 352:544–545

    Article  PubMed  CAS  Google Scholar 

  30. Meaux-Ruault N, Magy N, Gil H et al (2003) Efficacy of thalidomide in refractory adult Still's disease: a new case report. Clin Exp Rheumatol 21:272

    PubMed  CAS  Google Scholar 

  31. Stern A, Riley R, Buckley L (2001) Worsening of mac-rophage activation syndrome in a patient with adult onset still's disease after initiation of etanercept therapy. J Clin Rheumatol 7:252–256

    Article  PubMed  CAS  Google Scholar 

  32. Rapini RP, Warner NB (2006) Relapsing polychondritis. Clin Dermatol 24:482–485

    Article  PubMed  Google Scholar 

  33. Hansson AS, Holmdahl R (2002) Cartilage-specific autoim-munity in animal models and clinical aspects in patients -focus on relapsing polychondritis. Arthritis Res 4: 296–301

    Article  PubMed  CAS  Google Scholar 

  34. Taneja V, Griffiths M, Behrens M et al (2003) Auricular chondritis in NOD.DQ8.Abetao (Ag7-/-) transgenic mice resembles human relapsing polychondritis. J Clin Invest 112:1843–1850

    PubMed  CAS  Google Scholar 

  35. Lang B, Rothenfusser A, Lanchbury JS et al (1993) Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 36:660–664

    Article  PubMed  CAS  Google Scholar 

  36. Zeuner M, Straub RH, Rauh G et al (1997) Relapsing poly-chondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol 24:96–101

    PubMed  CAS  Google Scholar 

  37. McAdam LP, O'Hanlan MA, Bluestone R et al (1976) Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 55:193–215

    Article  CAS  Google Scholar 

  38. Michet CJ Jr, McKenna CH, Luthra HS et al (1986) Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 104:74–78

    PubMed  Google Scholar 

  39. Frances C, el Rassi R, Laporte JL et al (2001) Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine (Baltimore) 80:173–179

    Article  CAS  Google Scholar 

  40. Firestein GS, Gruber HE, Weisman MH et al (1985) Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondri-tis and Behcet's disease. Am J Med 79:65–72

    Article  PubMed  CAS  Google Scholar 

  41. Rozin AP, Gez E, Bergman R (2005) Recurrent auricular chondritis and cartilage repair. Ann Rheum Dis 64: 783–784

    Article  PubMed  CAS  Google Scholar 

  42. Handler RP (2006) Leflunomide for relapsing polychondri-tis: successful longterm treatment. J Rheumatol 33:1916; author reply 1917

    PubMed  Google Scholar 

  43. Goldenberg G, Sangueza OP, Jorizzo JL (2006) Successful treatment of relapsing polychondritis with mycophenolate mofetil. J Dermatolog Treat 17:158–159

    Article  PubMed  Google Scholar 

  44. Vounotrypidis P, Sakellariou GT, Zisopoulos D et al (2006) Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 45:491–492

    Article  CAS  Google Scholar 

  45. Richez C, Dumoulin C, Coutouly X et al (2004) Successful treatment of relapsing polychondritis with infliximab. Clin Exp Rheumatol 22:629–631

    PubMed  CAS  Google Scholar 

  46. Carter JD (2005) Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol 32:1413

    PubMed  Google Scholar 

  47. Brewerton DA, Caffrey M, Nicholls A et al (1973) Reiter's disease and HL-A 27. Lancet 2:996–998

    Article  Google Scholar 

  48. Winchester R, Bernstein DH, Fischer HD et al (1987) The co-occurrence of Reiter's syndrome and acquired immuno-deficiency. Ann Intern Med 106:19–26

    PubMed  CAS  Google Scholar 

  49. Boeger CA, Wittwer H, Schattenkirchner M et al (2001) Treatment of ankylosing spondylitis with infliximab. Ann Rheum Dis 60:1159–1160

    Article  PubMed  CAS  Google Scholar 

  50. Gaylis N (2003) Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 30: 407–411

    PubMed  Google Scholar 

  51. Thielen AM, Barde C, Janer V et al (2007) Reiter syndrome triggered by adalimumab (Humira) and leflunomide (Arava) in a patient with ankylosing spondylarthropathy and Crohn disease. Br J Dermatol 156:188–189

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Kanazawa University, Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan

    Manabu Fujimoto & Kazuhiko Takehara

Authors
  1. Manabu Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiko Takehara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manabu Fujimoto .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik und Poliklinik für Dermatologie und Venerologie, Kerpener Str. 62, Köln, 50924, Germany

    Thomas Krieg

  2. Dept. Dermatology, Columbia University Medical Center, 12th Floor, Herbert Irving Pavilion 161 Fort Washington Ave, New York, NY, 10032, USA

    David R. Bickers

  3. Dept. Dermatology & Cutaneous Sciences, Kyoto University Graduate School of Medicine, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

    Yoshiki Miyachi

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fujimoto, M., Takehara, K. (2010). Skin Manifestations in Rheumatologic Disorders. In: Krieg, T., Bickers, D.R., Miyachi, Y. (eds) Therapy of Skin Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78814-0_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-78814-0_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-78813-3

  • Online ISBN: 978-3-540-78814-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation